Amy Calistri
Stock of the Month
Stephen Leeb
Income Performance Report
Roger Conrad
The Utility Forecaster
Paul McWilliams
Next Inning

Waste Management (WM): No glamor, but reliability


Bookmark and Share
Article Index
Waste Management (WM): No glamor, but reliability
Page 2
All Pages
by Stephen Leeb, editor Income Performance Letter

Stephen LeebManaging waste is about as far from glamorous as you can get. But it’s essential, and offers relatively reliable growth and defensive qualities that should appeal to conservative investors.

Waste Management (WM) is the largest waste-management operator in the U.S. and Canada, with about a 25 percent market share.


The company serves 20 million municipal, commercial, industrial and residential customers throughout the U.S.

At year-end 2009, the company had 367 collection operations, 355 transfer stations, 273 active landfill disposal sites, 16 waste-to-energy plants, 134 recycling plants and 111 beneficial-use landfill gas projects.
Advertisement
Banner

Waste Management’s largest business is collection of solid waste (58 percent of 2009 revenues). The company picks up garbage and takes it to transfer stations, recycling facilities or directly to disposal sites.

The work is performed under multiyear contracts, giving the company exclusivity and largely predictable revenue streams.

Waste Management’s main disposal sites for trash are landfills. The company owns the largest solid-waste landfill network in North America. It also operates five hazardous-waste landfills in the U.S.

Waste Management also owns or operates more than 20 waste-to-energy facilities and power-production plants in the U.S. There, solid waste is burned to create steam, which is sold directly to end users or used to produce electricity and sold in wholesale markets.

In addition to several recycling and waste-reduction initiatives, the company continues to invest in waste conversion to energy. Recently, it bought a 40 percent stake in Shanghai Environment Group, the leading waste-to-energy company in China, which has surpassed the U.S. as the largest waste-generator in the world.

Waste Management also is expanding its health-care services business, which helps in managing waste and reducing waste-related costs. These green and health-care operations together, while a small part of the company, offer good growth opportunities.

Waste Management has a good balance sheet. It has a sizeable $8.4 billion in total debt, but this has remained steady, and the debt maturity dates are well spread out over several decades.

Management expects to generate around $1.3 billion in free cash flow this year, more than enough to cover debt and dividend obligations.

Waste Management has raised its dividend twice since late 2008, by a total of 17 percent. Shares trade at 14 times projected 2011 earnings. Current yield: 3.9 percent. Buy for predictable cash flow, conservative growth and good dividend income.

Learn more about this financial newsletter at Stephen Leeb's Income Performance Letter.

Banner
News Flash

Linkedin: Professional profits
by Leo Fasciocco, editor Ticker Tape Digest

Online professional network operator Linkedin (LNKD) recently moved above its technical breakout point of $108.53. We now target a move to $138.


Read more...

 

Tap in to water stocks
by Doug Fabian, editor Making Money Alert

As we prepare for the summer heat, water presents a significant investment opportunity -- especially as states such as California and Texas face droughts. The PowerShares Water Resource ETF (PHO) presents one way to invest in water's untapped potential.


Read more...


   

Pax World: High yield exception
by Amy Calistri, editor The Daily Paycheck

I generally prefer closed-end or exchange-traded funds because the fees tend to be lower. But I made a special case for Pax World High Yield Bond (PAXHX); this high-yield bond fund is my only open-ended mutual fund holding.


Read more...

 

Amgen: Biotech DRIP
by Chuck Carlson, editor DRIP Investor

Amgen (AMGN) is one of the oldest and largest players in the biotechnology area. It pioneered the development of products based on advances in recombinant DNA and molecular biology, launching the biotechnology industry’s first blockbuster medicines.


Read more...

 

Fidelity fund expert looks to Japan
by Jim Lowell, editor Fidelity Investor

In my May Marketwatch investment strategy column I noted, “Set against the backdrop of having already been thrown out with the Eurozone’s bathwater, I like Japan’s marketplace overall and, more specifically, their small cap marketplace which caters to domestic counter traffic.”


Read more...

 

MOO: Market Vectors Agribusiness
by Doug Fabian, editor Making Money Alert

Everyone needs food to survive, so wouldn't it be great to make money from it? We can. The global agriculture business provides a fairly stable investment with growth potential. In particular, I am looking at Market Vectors Agribusiness ETF (MOO).


Read more...

 

Celgene: Selloff creates opportunity
by J. Royden Ward, editor Cabot Benjamin Graham Value Letter

Celgene (CELG) develops and assists in the marketing of drugs to treat cancer and infl ammatory diseases. It acquired several companies recently, which will expand its product line and add promising products in various stages of development.


Read more...

 

Senior housing reits for income
by Brian Hicks, editor Wealth Advisory

Omega Healthcare Investors (OHI) and Medical Properties Trust (MPW) caters to the senior housing/assisted living facilities. Given the growing senior population, it makes sense to be somewhat over-exposed to companies that target this market.


Read more...

 

Buffett: Still banking on banks
by Ron Rowland, editor All Star Investor

Wise investors zero in on conflicting data points. Warren Buffett, the wisest investor of all, provided plenty to consider at the Berkshire Hathaway annual meeting. 


Read more...

 

Questcor: 'Exponential demand'
by Dennis Slothower, editor Stealth Stocks

Questcor Pharmaceuticals (QCOR), our latest featured stock of the month, is a biopharmaceutical company whose primary product helps patients with serious, difficult-to-treat medical conditions.


Read more...

 



Banner



Close
Select Offer: Schwab Options Market Commentary